Double blind placebo controlled study to assess the expression of IgE [immunoglobulin E] on basophils and dendritic cells during omalizumab treatment

Trial Profile

Double blind placebo controlled study to assess the expression of IgE [immunoglobulin E] on basophils and dendritic cells during omalizumab treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2011

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 01 Jul 2011 Last checked against ClinicalTrials.gov record.
    • 26 Aug 2010 Results published in Respiratory Medicine.
    • 27 Jul 2009 Actual end date (1 Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top